NCT00771368

Brief Summary

The purpose of this study is to determine if gaseous nitric oxide is effective in the treatement of bacteria in MRSA positive ulcers

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at P25-P50 for phase_1

Timeline
Completed

Started Jan 2009

Shorter than P25 for phase_1

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 10, 2008

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 13, 2008

Completed
3 months until next milestone

Study Start

First participant enrolled

January 1, 2009

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2009

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2009

Completed
Last Updated

January 19, 2012

Status Verified

January 1, 2012

Enrollment Period

4 months

First QC Date

October 10, 2008

Last Update Submit

January 18, 2012

Conditions

Outcome Measures

Primary Outcomes (1)

  • Reduction in bacteria

    Post Treatment Day 3

Secondary Outcomes (1)

  • Incidence of adverse events

    3 days

Study Arms (1)

Nitric Oxide

EXPERIMENTAL

gaseous nitric oxide delivered topically for 30 minutes

Drug: Nitric Oxide

Interventions

1 % Gaseous Nitric Oxide, delivered for 30 minutes daily for 3 consecutive days

Nitric Oxide

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Must have given written informed consent
  • Must be 19 years of age or over
  • Must have an ulcer or lesion in which the presence of MRSA has been positively identified but which is not clinically infected.
  • Must have an Ulcer / Lesion size not to extend beyond the inner borders of the wound cover

You may not qualify if:

  • Is a female who is pregnant, nursing, or of child bearing potential who is not using an adequate form of contraception (or abstinence)
  • Is \< 19 years of age
  • Has a clinically infected ulcer
  • Has an Ulcer / Lesion that is currently treated or has been treated with a topical antimicrobial agent during 3 days prior to enrolment.
  • Has been using systemic antibiotics during 7 days prior to enrolment into this study.
  • Has an Ulcer / Lesion which is identified as malignant in origin (e.g., Marjolin's ulcer)
  • Has an Ulcer / Lesion size beyond the inner borders of the wound cover
  • Is septic or has other signs of an invasive infection
  • Has used any other investigational product within 30 days preceding study participation.
  • Suffers from a condition, which, in the opinion of the Investigator,would compromise his or her safety.
  • Suffers from a condition which, in the opinion of the Investigator, would compromise the quality of the data.
  • Has a known allergy to any of the products that are part of this protocol
  • Suffers from a condition which, in the opinion of the Investigator, would seriously interfere negatively with the normal parameters of immune response to an infection.
  • Is using any of the prohibited concomitant medications or treatments

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Vancouver General Hospital

Vancouver, British Columbia, V5Z 1M9, Canada

Location

MeSH Terms

Conditions

Leg UlcerPressure Ulcer

Interventions

Nitric Oxide

Condition Hierarchy (Ancestors)

Skin UlcerSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Reactive Nitrogen SpeciesFree RadicalsInorganic ChemicalsNitrogen OxidesNitrogen CompoundsOxidesOxygen CompoundsOrganic Chemicals

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

October 10, 2008

First Posted

October 13, 2008

Study Start

January 1, 2009

Primary Completion

May 1, 2009

Study Completion

June 1, 2009

Last Updated

January 19, 2012

Record last verified: 2012-01

Locations